| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.35 | 3e-15 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.51 | 1e-12 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-12 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-12 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.32 | 2e-10 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.3 | 2e-10 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.28 | 4e-10 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-08 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-08 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.24 | 8e-08 |